Mari Michele Nakamura, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Infective Agents | 3 | 2024 | 972 | 1.410 |
Why?
|
| Hospitals, Pediatric | 9 | 2023 | 1775 | 1.370 |
Why?
|
| Antiviral Agents | 4 | 2021 | 2987 | 1.270 |
Why?
|
| Influenza, Human | 4 | 2023 | 1479 | 0.900 |
Why?
|
| Patient Readmission | 7 | 2018 | 3114 | 0.860 |
Why?
|
| Orbital Cellulitis | 1 | 2022 | 33 | 0.830 |
Why?
|
| Staphylococcal Infections | 3 | 2022 | 1400 | 0.750 |
Why?
|
| Meningitis, Bacterial | 1 | 2022 | 218 | 0.730 |
Why?
|
| Influenza Vaccines | 2 | 2022 | 738 | 0.680 |
Why?
|
| Community-Acquired Infections | 3 | 2024 | 465 | 0.670 |
Why?
|
| Streptococcal Infections | 1 | 2022 | 638 | 0.620 |
Why?
|
| Communicable Diseases | 2 | 2024 | 880 | 0.590 |
Why?
|
| Fluoroquinolones | 1 | 2018 | 310 | 0.560 |
Why?
|
| Anti-Bacterial Agents | 10 | 2024 | 7181 | 0.540 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 687 | 0.520 |
Why?
|
| Quality Indicators, Health Care | 5 | 2018 | 1831 | 0.510 |
Why?
|
| Child | 31 | 2024 | 77709 | 0.500 |
Why?
|
| Bacterial Infections | 2 | 2021 | 1401 | 0.460 |
Why?
|
| Carrier State | 2 | 2010 | 518 | 0.450 |
Why?
|
| Staphylococcus aureus | 3 | 2022 | 1451 | 0.440 |
Why?
|
| Reimbursement, Incentive | 2 | 2015 | 540 | 0.440 |
Why?
|
| Diffusion of Innovation | 2 | 2015 | 725 | 0.430 |
Why?
|
| Electronic Health Records | 4 | 2023 | 4468 | 0.430 |
Why?
|
| Pneumonia, Viral | 2 | 2021 | 3240 | 0.420 |
Why?
|
| Bronchiolitis | 1 | 2017 | 458 | 0.390 |
Why?
|
| Immunization | 2 | 2022 | 1256 | 0.370 |
Why?
|
| Antibodies, Monoclonal | 3 | 2023 | 9274 | 0.370 |
Why?
|
| Pneumonia | 2 | 2024 | 2133 | 0.360 |
Why?
|
| Outpatients | 1 | 2018 | 1486 | 0.360 |
Why?
|
| Bacteriological Techniques | 1 | 2010 | 277 | 0.340 |
Why?
|
| Pharynx | 1 | 2010 | 413 | 0.300 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2017 | 1209 | 0.290 |
Why?
|
| Quality Assurance, Health Care | 2 | 2014 | 2212 | 0.290 |
Why?
|
| Bordetella pertussis | 1 | 2006 | 43 | 0.290 |
Why?
|
| Medicaid | 2 | 2017 | 2736 | 0.280 |
Why?
|
| Patient Access to Records | 1 | 2007 | 118 | 0.280 |
Why?
|
| Nose | 1 | 2010 | 509 | 0.280 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2015 | 1205 | 0.270 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2023 | 1164 | 0.270 |
Why?
|
| Medical Informatics | 1 | 2013 | 745 | 0.270 |
Why?
|
| Infant | 10 | 2022 | 35136 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 1 | 2022 | 7279 | 0.250 |
Why?
|
| Adolescent | 15 | 2024 | 85781 | 0.240 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 7913 | 0.240 |
Why?
|
| Research Design | 1 | 2020 | 5987 | 0.240 |
Why?
|
| Child, Preschool | 11 | 2022 | 41006 | 0.240 |
Why?
|
| Vaccination | 2 | 2022 | 3278 | 0.230 |
Why?
|
| Immunocompromised Host | 3 | 2022 | 847 | 0.220 |
Why?
|
| Quality Improvement | 3 | 2014 | 3749 | 0.220 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.210 |
Why?
|
| Methicillin Resistance | 1 | 2002 | 198 | 0.200 |
Why?
|
| Health Care Surveys | 3 | 2015 | 2453 | 0.200 |
Why?
|
| Humans | 37 | 2024 | 744343 | 0.200 |
Why?
|
| Retrospective Studies | 14 | 2024 | 77449 | 0.190 |
Why?
|
| Twins, Monozygotic | 1 | 2022 | 458 | 0.190 |
Why?
|
| Streptococcus agalactiae | 1 | 2022 | 375 | 0.190 |
Why?
|
| Ceftriaxone | 1 | 2021 | 168 | 0.180 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2006 | 1122 | 0.180 |
Why?
|
| Feedback | 1 | 2024 | 795 | 0.180 |
Why?
|
| Pediatrics | 4 | 2020 | 3475 | 0.180 |
Why?
|
| Aspergillosis | 1 | 2022 | 235 | 0.180 |
Why?
|
| Hospitals | 4 | 2024 | 3952 | 0.180 |
Why?
|
| Nasopharynx | 1 | 2002 | 379 | 0.180 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2022 | 768 | 0.180 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 275 | 0.170 |
Why?
|
| Vancomycin | 1 | 2022 | 501 | 0.170 |
Why?
|
| Osteomyelitis | 1 | 2023 | 402 | 0.160 |
Why?
|
| Alanine | 1 | 2021 | 572 | 0.160 |
Why?
|
| Abscess | 1 | 2022 | 607 | 0.160 |
Why?
|
| Seizures | 2 | 2022 | 2859 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2013 | 4371 | 0.150 |
Why?
|
| Blood Cell Count | 1 | 2018 | 403 | 0.150 |
Why?
|
| Infant, Newborn | 5 | 2022 | 25625 | 0.150 |
Why?
|
| Aspartate Aminotransferases | 1 | 2018 | 418 | 0.140 |
Why?
|
| Drug Combinations | 1 | 2022 | 1959 | 0.140 |
Why?
|
| Bilirubin | 1 | 2018 | 425 | 0.140 |
Why?
|
| Trust | 1 | 2020 | 505 | 0.140 |
Why?
|
| Alanine Transaminase | 1 | 2018 | 592 | 0.130 |
Why?
|
| Societies, Hospital | 1 | 2015 | 6 | 0.130 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 612 | 0.130 |
Why?
|
| Hospitals, Community | 1 | 2017 | 348 | 0.130 |
Why?
|
| Cost Control | 1 | 2017 | 624 | 0.130 |
Why?
|
| Risk Adjustment | 1 | 2018 | 594 | 0.120 |
Why?
|
| Chronic Disease | 2 | 2013 | 9146 | 0.120 |
Why?
|
| Risk Factors | 8 | 2024 | 72290 | 0.120 |
Why?
|
| Growth Charts | 1 | 2015 | 61 | 0.120 |
Why?
|
| Drug Approval | 1 | 2021 | 742 | 0.120 |
Why?
|
| Logistic Models | 3 | 2022 | 13408 | 0.120 |
Why?
|
| Drug Hypersensitivity | 1 | 2023 | 884 | 0.120 |
Why?
|
| Attitude to Computers | 1 | 2015 | 202 | 0.120 |
Why?
|
| United States | 9 | 2021 | 69872 | 0.120 |
Why?
|
| Hospital Bed Capacity | 1 | 2015 | 214 | 0.120 |
Why?
|
| Long QT Syndrome | 1 | 2018 | 453 | 0.120 |
Why?
|
| Hypersensitivity | 1 | 2023 | 1102 | 0.120 |
Why?
|
| Heart Diseases | 2 | 2022 | 2788 | 0.120 |
Why?
|
| Withholding Treatment | 1 | 2018 | 599 | 0.110 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 1584 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 1855 | 0.110 |
Why?
|
| Neutropenia | 1 | 2018 | 895 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 15540 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2022 | 6171 | 0.110 |
Why?
|
| Anticonvulsants | 1 | 2022 | 1916 | 0.110 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 1978 | 0.110 |
Why?
|
| Faculty, Medical | 1 | 2020 | 1181 | 0.100 |
Why?
|
| Infant, Premature, Diseases | 1 | 2017 | 706 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2020 | 23338 | 0.100 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 3176 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2018 | 3913 | 0.090 |
Why?
|
| Pandemics | 2 | 2021 | 8388 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 4933 | 0.090 |
Why?
|
| Child Welfare | 1 | 2014 | 523 | 0.090 |
Why?
|
| Insurance Claim Review | 1 | 2014 | 720 | 0.090 |
Why?
|
| Male | 13 | 2021 | 350118 | 0.090 |
Why?
|
| Hospitalization | 3 | 2023 | 10262 | 0.080 |
Why?
|
| Attitude of Health Personnel | 2 | 2015 | 3843 | 0.080 |
Why?
|
| Female | 13 | 2021 | 380194 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 3610 | 0.080 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 840 | 0.080 |
Why?
|
| Child Health Services | 1 | 2014 | 667 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 2208 | 0.080 |
Why?
|
| Registries | 2 | 2017 | 8089 | 0.080 |
Why?
|
| Program Development | 1 | 2013 | 1316 | 0.070 |
Why?
|
| Prevalence | 4 | 2017 | 15226 | 0.070 |
Why?
|
| Systems Integration | 1 | 2007 | 440 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2020 | 4687 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 7785 | 0.060 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 950 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2013 | 2488 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2017 | 3209 | 0.060 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2010 | 981 | 0.060 |
Why?
|
| Mental Health | 1 | 2017 | 3019 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 5751 | 0.060 |
Why?
|
| Asthma | 1 | 2022 | 6011 | 0.060 |
Why?
|
| Respiratory Tract Diseases | 1 | 2008 | 722 | 0.060 |
Why?
|
| Tennessee | 1 | 2002 | 117 | 0.050 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2002 | 143 | 0.050 |
Why?
|
| Aspergillus | 1 | 2022 | 85 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2014 | 2494 | 0.050 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 658 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 14722 | 0.050 |
Why?
|
| Comorbidity | 2 | 2022 | 10388 | 0.050 |
Why?
|
| Glutamic Acid | 1 | 2006 | 1169 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2006 | 7722 | 0.050 |
Why?
|
| Age Factors | 1 | 2017 | 18370 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2020 | 5788 | 0.050 |
Why?
|
| Penicillins | 1 | 2023 | 380 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2003 | 2050 | 0.040 |
Why?
|
| Child, Hospitalized | 1 | 2021 | 174 | 0.040 |
Why?
|
| Professional Autonomy | 1 | 2020 | 177 | 0.040 |
Why?
|
| Emotional Intelligence | 1 | 2020 | 136 | 0.040 |
Why?
|
| Time Factors | 2 | 2018 | 40075 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3920 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2017 | 6600 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 4320 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2008 | 2149 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2002 | 1877 | 0.040 |
Why?
|
| Massachusetts | 1 | 2008 | 8663 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 40561 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 12245 | 0.030 |
Why?
|
| Consensus | 1 | 2024 | 2959 | 0.030 |
Why?
|
| Genome | 1 | 2003 | 1808 | 0.030 |
Why?
|
| Urban Population | 1 | 2002 | 2021 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2024 | 2266 | 0.030 |
Why?
|
| Interpersonal Relations | 1 | 2020 | 1425 | 0.030 |
Why?
|
| Adult | 3 | 2024 | 214055 | 0.030 |
Why?
|
| New York | 1 | 2015 | 886 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2006 | 3848 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2006 | 9438 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 1769 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2020 | 2682 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 2569 | 0.030 |
Why?
|
| Accreditation | 1 | 2014 | 450 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2013 | 455 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 1439 | 0.020 |
Why?
|
| Obesity | 2 | 2023 | 12745 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 56430 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 25043 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 867 | 0.020 |
Why?
|
| Data Collection | 1 | 2015 | 3341 | 0.020 |
Why?
|
| RNA Caps | 1 | 2003 | 74 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2003 | 255 | 0.010 |
Why?
|
| Polyadenylation | 1 | 2003 | 117 | 0.010 |
Why?
|
| HIV Infections | 1 | 2008 | 16718 | 0.010 |
Why?
|
| Curriculum | 1 | 2014 | 3605 | 0.010 |
Why?
|
| Gene Library | 1 | 2003 | 1074 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2013 | 3313 | 0.010 |
Why?
|
| Neoplasms | 1 | 2008 | 21683 | 0.010 |
Why?
|
| Genes | 1 | 2003 | 1893 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 2008 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2003 | 2715 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2003 | 1783 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 39050 | 0.010 |
Why?
|
| Algorithms | 1 | 2014 | 13881 | 0.010 |
Why?
|
| Animals | 2 | 2022 | 168757 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 4803 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2003 | 21827 | 0.000 |
Why?
|
| Middle Aged | 1 | 2014 | 213383 | 0.000 |
Why?
|
| Mice | 1 | 2003 | 81183 | 0.000 |
Why?
|